Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (41)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nath, U.
Right arrow Articles by Burn, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nath, U.
Right arrow Articles by Burn, D. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 124, No. 7, 1438-1449, July 2001
© 2001 Oxford University Press

The prevalence of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome) in the UK

U. Nath1, Y. Ben-Shlomo3, R. G. Thomson2, H. R. Morris4, N. W. Wood5, A. J. Lees4 and D. J. Burn1

1 Department of Neurology and 2 Department of Epidemiology and Public Health, School of Health Sciences, University of Newcastle upon Tyne, 3 Department of Social Medicine, Bristol University, 4 Reta Lila Weston Institute of Neurological Sciences and Institute of Neurology and 5 Neurogenetics Department, Institute of Neurology, London, UK

Correspondence to: Dr D. J. Burn, Consultant and Senior Lecturer in Neurology, Regional Neurosciences Centre, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BE, UK E-mail: d.j.burn{at}ncl.ac.uk

We performed a study to estimate the point prevalence of progressive supranuclear palsy (PSP) in the UK at national, regional and community levels. A `Russian doll' design was used in which the population denominator for each of the three studies was successively smaller, whilst the method of case ascertainment became increasingly more rigorous. The NINDS-SPSP (National Institute of Neurological Disorders and the Society for Progressive Supranuclear Palsy) diagnostic criteria for PSP were applied throughout the study for case definition. The national study identified cases using passive referral mechanisms [e.g. the British Neurological Surveillance Unit (BNSU), PSP (Europe) Association patient register]. We identified 577 cases of PSP, giving a national prevalence estimate of 1.0 per 100 000 [95% confidence interval (CI) 0.9–1.1]. The North of England regional study used active `multiple source' case ascertainment from a collaborative network of neurologists and non-neurologists. We identified 80 cases of PSP in this study, giving a crude and age-adjusted prevalence of 3.1 (95% CI 2.4–3.8) and 2.4 (1.9–3.0) per 100 000, respectively. Of these 80 cases, 51 patients (65%) were referred initially to non-neurologists and 10 patients (13%) had not seen a neurologist at any stage of their illness. The proportion of female cases was significantly greater in the regional than in the national study (61% versus 44%; P < 0.02). Cases referred to non-neurologists were significantly older than those referred to neurologists in the regional study (median age 73 versus 69.5 years; P < 0.01). Patients in the community study were identified via diagnostic and therapeutic registers from a representative sample of general practices in Newcastle upon Tyne. We identified 17 cases of PSP, yielding crude and age-adjusted prevalences of 6.5 (95% CI 3.4–9.7) and 5.0 (95% CI 2.5–7.5) per 100 000, respectively. Seven of the 17 cases (41%) had not previously been diagnosed as PSP. This study suggests that PSP is more common than previously considered, is commonly misdiagnosed and that the majority of cases are not initially referred to neurologists. The study also confirms the importance of active and detailed case ascertainment in ensuring reliable prevalence estimates.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
BrainHome page
G. Bensimon, A. Ludolph, Y. Agid, M. Vidailhet, C. Payan, P. N. Leigh, and for the NNIPPS Study Group
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
Brain, January 1, 2009; 132(1): 156 - 171.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
A. Schrag, C. Selai, N. Quinn, A. Lees, I. Litvan, A. Lang, Y. Poon, J. Bower, D. Burn, and J. Hobart
Measuring quality of life in PSP: The PSP-QoL.
Neurology, July 11, 2006; 67(1): 39 - 44.
[Abstract] [Full Text] [PDF]


Home page
ptjournalHome page
C. Zampieri and R. P Di Fabio
Progressive Supranuclear Palsy: Disease Profile and Rehabilitation Strategies
Physical Therapy, June 1, 2006; 86(6): 870 - 880.
[Full Text] [PDF]


Home page
BrainHome page
D. C. Paviour, S. L. Price, M. Jahanshahi, A. J. Lees, and N. C. Fox
Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy
Brain, April 1, 2006; 129(4): 1040 - 1049.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
D. J. Burn
Commentary on: Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism, by D. Williams, R. de Silva, D. Paviour, et al. (Brain-2004-01045.R1)
Brain, June 1, 2005; 128(6): 1235 - 1236.
[Full Text] [PDF]


Home page
BrainHome page
N. J. Cordato, A. J. Duggins, G. M. Halliday, J. G. L. Morris, and C. Pantelis
Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy
Brain, June 1, 2005; 128(6): 1259 - 1266.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
U Nath, R Thomson, R Wood, Y Ben-Shlomo, A Lees, C Rooney, and D Burn
Population based mortality and quality of death certification in progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)
J. Neurol. Neurosurg. Psychiatry, April 1, 2005; 76(4): 498 - 502.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
D C Paviour, J M Schott, J M Stevens, T Revesz, J L Holton, M N Rossor, A J Lees, and N C Fox
Pathological substrate for regional distribution of increased atrophy rates in progressive supranuclear palsy
J. Neurol. Neurosurg. Psychiatry, December 1, 2004; 75(12): 1772 - 1775.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
M B Muzaimi, J Thomas, S Palmer-Smith, L Rosser, P S Harper, C M Wiles, D Ravine, and N P Robertson
Population based study of late onset cerebellar ataxia in south east Wales
J. Neurol. Neurosurg. Psychiatry, August 1, 2004; 75(8): 1129 - 1134.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
U. Nath, Y. Ben-Shlomo, R.G. Thomson, A.J. Lees, and D.J. Burn
Clinical features and natural history of progressive supranuclear palsy: A clinical cohort study
Neurology, March 25, 2003; 60(6): 910 - 916.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
D. Caparros-Lefebvre, N. Sergeant, A. Lees, A. Camuzat, S. Daniel, A. Lannuzel, A. Brice, E. Tolosa, A. Delacourte, and C. Duyckaerts
Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy
Brain, April 1, 2002; 125(4): 801 - 811.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
N. J. Cordato, C. Pantelis, G. M. Halliday, D. Velakoulis, S. J. Wood, G. W. Stuart, J. Currie, M. Soo, G. Olivieri, G. A. Broe, et al.
Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy
Brain, March 1, 2002; 125(4): 789 - 800.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.